ľֱ

EndoBreak: Oral Semaglutide Success; Methyldopa for T1D

— News and commentary from the endocrinology world

MedpageToday

This article is a collaboration between ľֱ and:

Findings from the first of Novo Nordisk's 10 phase III trials testing its were released this week, showing that 3 mg, 7 mg, and 14 mg of the pill were superior to placebo for weight loss. (Reuters)

When taken three times a day, the blood pressure drug methyldopa was successful at onset in about 60% of those at risk. A larger clinical trial is scheduled for this spring. (ScienceDaily)

After a 500-lb man was rejected by his health insurance for gastric bypass, one surgeon offered to perform the . (Los Angeles Times)

Hormone-replacement therapy (HT) may help protect against in older women, a new study found. "The protective benefits continued even after stopping HT," said JoAnn Pinkerton, MD, executive director of the North American Menopause Society, in a statement. (Menopause)

Talk-show host Wendy Williams announced this week that she has . (CNN)

Only about 25% of transgender women on the traditional regimen of spironolactone and estrogens were able to within the typical female physiologic range, with the majority unable to suppress levels into this range. "Identification of reasons why certain patients have better testosterone suppression could help improve anti-androgen therapy and allow for targeted interventions to advance the U.S. medical regimen for transgender women," the researchers suggested in the new report. (Endocrine Practice)

Four types of viruses were found to produce hormones analogous to insulin, investigators found. "Our research may help open up a new field that we might call ," said Emrah Altindis, PhD, of Joslin Diabetes Center in Boston, in a statement. (PNAS)

The American Diabetes Association announced John J. Agos as its new this week.

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.